Rallybio (RLYB) Projected to Release Earnings on Thursday

Rallybio (NASDAQ:RLYB) is expected to post its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($1.44) per share for the quarter. Parties can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, October 27, 2026 at 7:00 AM ET.

Rallybio (NASDAQ:RLYB) last released its quarterly earnings data on Tuesday, October 27th. The company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.44) by $0.96. Rallybio had a negative net margin of 911.07% and a negative return on equity of 31.44%.

Rallybio Stock Performance

Shares of Rallybio stock opened at $15.86 on Wednesday. The stock has a market capitalization of $85.33 million, a PE ratio of -3.65 and a beta of -0.73. Rallybio has a 52-week low of $3.67 and a 52-week high of $17.57. The company has a 50-day simple moving average of $16.69 and a two-hundred day simple moving average of $12.97.

Rallybio Dividend Announcement

The company also recently declared a special dividend, which will be paid on Friday, November 13th. Stockholders of record on Thursday, November 5th will be issued a dividend of $13.56 per share.

Wall Street Analyst Weigh In

RLYB has been the topic of a number of recent analyst reports. Wall Street Zen raised shares of Rallybio from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. Weiss Ratings lowered shares of Rallybio from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Rallybio Company Profile

Rallybio Corporation is a clinical-stage biotechnology company focused on developing medicines for patients with rare diseases, with an emphasis on conditions that affect maternal and fetal health, as well as other serious disorders with limited treatment options. The company is headquartered in New Haven, Connecticut, and its programs are intended for specialized patient populations in the United States and international markets.

Rallybio’s lead program, RLYB212, is being developed to prevent fetal and neonatal alloimmune thrombocytopenia, a rare condition in which maternal antibodies attack fetal platelets during pregnancy.